Samoilovich, E.O., Yermolovich, M.A., Kotova, I.F., Svirchevskaya, E.Yu., Shimanovich, V.P., Kozhemyakin, A.K., Protas I.I., Feldman, E.V.

Experience of acute flaccid paralysis surveillance in Belarus

Research Institute of Epidemiology and Microbiology, Republican Center of Hygiene, Epidemiology and Public Health, Minsk, Republic of Belarus

The ten-years experience of acute flaccid paralysis (AFP) surveillance in Belarus has been summarized. Among 456 AFP cases reported from 1996 to 2005, 11 were classified as vaccine-associated paralytic poliomyelitis (VAPP), 445 — as non-polio AFP. The risk of VAPP for the period 1996 — 2001 was 1 case per 745,000 used doses of oral poliovaccine (OPV). For the recipients of OPV the risk was 1 case per 911,700 doses and for the first-dose recipients — 1 case per 96,000 doses. The high incidence of VAPP was a reason for implementation of sequential polio vaccination schedule in 2000. Guillain-Barre syndrome dominated among non-polio AFP (39.3% of cases); more rare were traumatic neuritis (27.9% of cases), transient monoparalysis (12.1%), myelitis (7.6%). Non-polio AFP differed from VAPP by following epidemiological and virological characteristics: predominance of previously repeatedly vaccinated against poliomyelitis; development of paralysis in long-term period after vaccination; isolation of non-polio viruses belonged to three serotypes of Coxsackie B viruses (B1, B4, B6) and six serotypes of Echo viruses (6, 7, 11, 14, 24, 25) in 8.1% of cases; absence of typical for polio residual paralyses in patients who excreted vaccine polioviruses.
Zh. Mikrobiol. (Moscow), 2007, No. 2, P. 24—31